HC Wainwright & Co. Maintains Buy on vTv Therapeutics, Lowers Price Target to $42

Benzinga Newsdesk www.benzinga.com Negative 49.4%

Neg 49.4% Neu 0% Pos 0%

HC Wainwright & Co. analyst Emily Bodnar maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and lowers the price target from $45 to $42.